“Amycretin mimics the action of two peptide hormones in one single molecule.”
Amycretin functions as both an amylin and glucagon-like peptide-1 (GLP-1) receptor agonist. Both of these hormones play a key role in regulating appetite and the feeling of hunger and have been shown to contribute to weight loss.
GLP-1 based treatment options are currently administered via injections. Amylin-based treatments undergoing clinical development also use this delivery method. There are no tablet-form treatment options targeting both of these biologies.
In a single-centre, placebo-controlled, double-blinded phase 1 study, adult participants with a BMI of 25.0-39.9 kg/m2 without diabetes were randomized to receive amycretin or a placebo once a day for up to 12 weeks.
The research, conducted by Novo Nordisk A/S and a clinical research unit in the US, consisted of two parts: single- and multiple-ascending dose studies. In the single-ascending dose part, doses of amycretin were tested orally, starting at 1 mg per day and increasing to 25 mg. The 10-day multiple-ascending doses study investigated doses ranging from 3 to 12 mg, while the 12-week multiple-ascending doses study involved step-wise dose escalation, starting at 3 mg and reaching a final dose of 2×50 mg.
In the first-in-human trial, amycretin appeared to have a safe and tolerable profile consistent with the drug receptor classes. Side effects were mainly mild to moderate in severity and of gastrointestinal nature, including nausea and vomiting.
Sure, the following shows the revised text: “After the trial, it was found that participants who took amycretin experienced greater weight loss compared to those who took the placebo. Those taking 50 mg of amycretin lost an average of 10.4% of their body weight after 12 weeks of treatment, while those who took the maximum tested dose of 2x50mg experienced a 13.1% reduction in body weight. In contrast, those taking the placebo only lost an average of 1.1% of their body weight during the same period.”
Notably, at the end of the treatment period, weight loss had not reached a plateau for participants taking amycretin, indicating the potential for further weight loss with extended use.
The study’s authors conclude that daily oral amylin treatment in adults with overweight or obesity and without diabetes demonstrated a safe and tolerable profile, aligning with the drug receptor classes, and resulted in significant reductions in body weight.
“A single molecule that targets both amylin and GLP-1 biology in a tablet form could provide a more convenient approach to improving outcomes for individuals with overweight or obesity.”
“However, larger and longer studies are necessary to fully evaluate the drug’s safety profile and potential.”